Media Coverage
Caladrius Biosciences enrolling patients in its coronavirus-induced lung damage treatment study
October 15, 2020

For link to original source, please click here.
Read MoreCell therapy improves coronary flow reserve in coronary microvascular dysfunction
May 15, 2020

For link to full article, please click here.
Read MoreCaladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
January 15, 2020

For link to original source, please click here.
Read MoreDr. Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 5, 2019

For link to full article, please click here.
Read MoreCaladrius unveils positive results of CLBS16 in CMD treatment
November 21, 2019

For link to full article, please click here.
Read MoreAHA: Caladrius single injection helps heart disease that hits women the hardest
November 21, 2019

For link to full article, please click here.
Read MoreSingle-Injection Cell Therapy Relieves CMD Symptoms
November 21, 2019

For link to full article, please click here.
Read MoreBRIEF-Caladrius Biosciences Reports Positive Results For CLBS16 From Escape-CMD Trial
November 21, 2019

For link to full article, please click here.
Read MoreRegulating Regeneration in Europe
April 9, 2019

Caladrius’ Vice President of Global Regulatory Affairs, William Sietsema, discusses the global regulatory environment for regenerative medicines and the Company’s priority review designations in the U.S. […]
Read MoreCaladrius Biosciences selected as BioNJ’s Emerging Company in the Spotlight
April 3, 2019

Caladrius Biosciences selected as BioNJ’s Emerging Company in the Spotlight
Read MoreFutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair
March 8, 2019

FutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair
Read MoreCell Therapy Trial Targets Type 1 Diabetes In Children
August 8, 2017

Clinical Leader’s Chief Editor, Ed Miseta, on Caladrius’ type 1 diabetes product candidate, CLBS03, progress through its phase 2 clinical trial.
Read MoreIn the Clinic: Caladrius Biosciences
July 20, 2017

BioWorld highlights Caladrius’ Sanford Project: T-Rex Study and upcoming milestones.
Read MoreType 1 Diabetes Cell Therapy Study Shows Promise in Pediatrics
July 20, 2017

MD Magazine discusses CLBS03 halfway through enrollment in the Sanford Project: Trex Study with Kurt Grifin, MD, PhD, director of clinical trials for the Sanford Project.
Read MorePractical Cure Project Update: Caladrius Biosciences Inc. Treg
April 21, 2017

Juvenile Diabetes Cure Alliance details previous CLBS03 study results and how the T regulatory cell technology works.
Read MoreClose Concerns Highlights Caladrius Type 1 Diabetes Program and Recent CIRM Grant
April 7, 2017

Close Concerns highlights Caladrius’s CLBS03 product candidate for the recent onset of type 1 diabetes in adolescence and the $12.2 million grant the program received from the California Institute for Regenerative Medicine (CIRM).
Read MoreCEOCFO Magazine Interview with Dr. David Mazzo
November 14, 2016

Caladrius Chief Executive Officer, Dr. David Mazzo, sits down with CEOCFO Magazine to discuss the Company’s cell therapy development pipeline and CDMO capabilities.
Read MoreStock News Now Interview with Dr. David Mazzo
October 19, 2016

Caladrius Chief Executive Officer, Dr. David Mazzo, discusses the Company’s cell therapy development and CDMO capabilities with Stock News Now’s Shelly Kraft at the Aegis 2016 Growth Conference in Las Vegas.
Read MoreA first for Fast Track designation
September 14, 2016

Caladrius Biosciences recently announced that its product candidate CLBS03 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for T1D to receive the designation.
Read MoreFDA Provides First Known Fast Track Designation for Type 1 Diabetes
September 5, 2016

Caladrius Biosciences has received FDA orphan drug designation for its CLBS03 therapy for people with type 1 diabetes who still have some residual beta cell function.
Read More